Acute and Severe Hypercalcemia Early After Kidney Transplantation in a Patient Previously Treated With Etelcalcetide
(2023) Transplant international — Vol. 36, p. 11271 [1-2] (2023)
Files
FoguenneetalAcuteandSevereHypercalcemiaEarlyAfterKidneyTransplantationinaPatientPreviouslyTreatedWithEtelcalcetideFINAL.pdf
Open Access - Adobe PDF
- 679.42 KB
Details
- Authors
Labriola, Laura 
- Abstract
- (en) DEAR EDITORS , Secondary hyperparathyroidism (SHPT) is frequent in patients with chronic kidney disease, especially in those on chronic haemodialysis (HD). Etelcalcetide, an intravenously-administered direct CaSR-agonist, is widely used worldwide for SHPT treatment. Yet, little has been described so far regarding its potential post-kidney transplant (KT) impact. We previously reported acute and severe hypercalcemia in the early post-transplant course in two patients previously treated with high-dose etelcalcetide. We here report another case. [...]
- Affiliations
Citations
Foguenne, M., Mourad, M., Buemi, A., Darius, T., Kanaan, N., Jadoul, M., Labriola, L., & Devresse, A. (2023). Acute and Severe Hypercalcemia Early After Kidney Transplantation in a Patient Previously Treated With Etelcalcetide. Transplant international, 36, 11271 [1-2]. https://doi.org/10.3389/ti.2023.11271 (Original work published 2023)